MPMichael Pollack

Michael Pollack

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Pollack has a total of 141 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiopulmonary Event Prevalence Before First Recorded COPD Diagnosis: A Retrospective Cohort Study Using the Clinical Practice Research Datalink

    by Richard Ek Russell, Vishnav Pradeep, Jonathan A Patrick, Christopher Llewellyn Morgan, Hungta Chen, Michael Pollack, Stephanie Dods, Hana Müllerová, Claus Franz Vogelmeier, Dave Singh, et al.

    Purpose: Post-COPD diagnosis, individuals have an increased risk of cardiopulmonary events, but little is known about the risk pre-diagnosis. This study extends previous evidence by investigating the prevalence of cardiopulmonary events before the first recorded COPD diagnosis, including within a standardised 3-year pre-diagnosis window, and compared cardiopulmonary risk with that of matched controls without COPD. Patients and Methods: This retrospective, cohort study included patients with a diagnosis of COPD in the Clinical Practice Research Datalink. The overall cohort included patients aged ≥ 35 years with a COPD diagnosis prior to December 31, 2019, from which an incident COPD cohort was identified with first recorded diagnosis between January 1, 2018-December 31, 2019 (index date). Cardiopulmonary events of interest were quantified within 3 years pre-index among those with ≥ 3 years of pre-index data and during the full look-back period. Matched non-COPD patients served as controls (1:2 ratio). Results: Of 426,854 patients with COPD, 77,428 were incident and matched 1:2 to patients without COPD. Patients in the incident cohort (mean age 67.4 [SD 13.6] years, 52% male, 94% White) had a higher prevalence of pre-diagnosis cardiopulmonary events than controls (76.2% versus 45.6%; odds ratio (OR) 3.8, [95% CI: 3.8– 3.9]). This association was consistent, with greater relative odds observed among those with ≥ 3 years pre-index data (n=70,062): 56.6% had a cardiopulmonary event vs 20.9% (OR 4.9, 95% CI: 4.8– 5.0) within 3 years pre-index, including severe cardiovascular events in 16,679 (23.8%) and respiratory events in 32,293 (46.1%) patients. Most common severe cardiovascular events were atrial fibrillation (58.1%), heart failure (46.1%) and myocardial infarction (15.1%). Before diagnosis, patients with incident COPD also had substantially greater HCRU, including 4.3-fold higher inpatient costs than matched controls. Conclusion: Cardiopulmonary events are frequent before COPD diagnosis, and signal elevated cardiopulmonary risk. Understanding the occurrence of antecedent cardiopulmonary events in COPD may enable earlier diagnosis and treatment.

  • Open Access

    Exacerbation and cardiopulmonary risk after prompt initiation of single-inhaler budesonide /glycopyrrolate/formoterol fumarate following COPD exacerbations: Insights from MITOS EROS (Japan) study

    by Koichiro Takahashi, Yuri Yoshida, Naoyuki Makita, Kenichiro Nishida, Michihiro Yoshimura, Zhao Cheng, Aaro Salosensaari, Catarina Camarinha, Reiko Yamaura, Marta Cuntin, et al.

  • Open Access

    Disease burden and health-related outcomes of patients discharged from hospital following a COPD exacerbation in the United States

    by Mohit Bhutani, Hana Müllerová, Deven Patel, Igor Barjaktarevic, Wei Jie Loke, Michael Pollack, Melissa Roberts, Diana Tamondong-Lachica, Fei Tang, Bartolome Celli


  • Open Access

    Practical strategies for achieving system change in the US: lessons and insights from the CONQUEST quality improvement programme

    by Alexander Evans, Jill VanWyk, Margee Kerr, Amy Couper, Wilson D. Pace, Yasir Tarabichi, Rachel Pullen, Michael Pollack, M. Bradley Drummond, Jill Ohar, et al.

    Background: Quality improvement programmes (QIPs) are designed to enhance patient outcomes by systematically introducing evidence-based clinical practices. The CONQUEST QIP focuses on improving the identification and management of patients with COPD in primary care. The process of developing CONQUEST, recruiting, preparing systems for participation, and implementing the QIP across three integrated healthcare systems (IHSs) is examined to identify and share lessons learned. Approach and development: This review is organized into three stages: 1) development, 2) preparing IHSs for implementation, and 3) implementation. In each stage, key steps are described with the lessons learned and how they can inform others interested in developing QIPs designed to improve the care of patients with chronic conditions in primary care. Stage 1 was establishing and working with steering committees to develop the QIP Quality Standards, define the target patient population, assess current management practices, and create a global operational protocol. Additionally, potential IHSs were assessed for feasibility of QIP integration into primary care practices. Factors assessed included a review of technological infrastructure, QI experience, and capacity for effective implementation. Stage 2 was preparation for implementation. Key was enlisting clinical champions to advocate for the QIP, secure participation in primary care, and establish effective communication channels. Preparation for implementation required obtaining IHS approvals, ensuring Health Insurance Portability and Accountability Act compliance, and devising operational strategies for patient outreach and clinical decision support delivery. Stage 3 was developing three IHS implementation models. With insight into the local context from local clinicians, implementation models were adapted to work with the resources and capacity of the IHSs while ensuring the delivery of essential elements of the programme. Conclusion: Developing and launching a QIP programme across primary care practices requires extensive groundwork, preparation, and committed local champions to assist in building an adaptable environment that encourages open communication and is receptive to feedback.

  • Open Access

    Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study

    by Myriam Calle Rubio, Juan Antonio Trigueros Carrero, Paula Chaparro Briones, Luciano Escudero Herrera, Michael Pollack, Ignacio Hernández Subirá, Joaquín Sánchez-Covisa

    Background: Single-inhaler triple therapy with budesonide/glycopyrronium/formoterol fumarate (BGF; Trixeo Aerosphere®) was approved in the European Union in December 2020 for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by dual therapy, and has been available in Spain since February 2022. This real-world, observational, retrospective cohort study, AURA Spain, describes the demographics, clinical characteristics, and healthcare resource utilization of patients initiating single-inhaler BGF triple therapy. Methods: Electronic medical records in the Spanish Healthcare System anonymized, integrated BIG-PAC® database were analyzed to identify COPD patients aged ≥ 40 years initiating single-inhaler BGF between 1 February 2022 and 31 January 2023. Results: Patients (N=482) had a mean (standard deviation, SD) age of 71.5 (10.0) years, mean BMI of 29.6 (6.2) kg/m2, most were aged ≥ 65 years (73.7%) and male (62.5%). Most were former (62.7%) or current (24.5%) smokers. Applying GOLD FEV1 thresholds, severity of COPD was moderate in 49.8% of patients, severe (41.9%), and very severe (6.5%). The most common comorbidities were hypertension (62.2%), dyslipidemia (56.8%), and anxiety (42.5%), and 85.9% had one or more cardiovascular-related comorbidity. Overall, 57.3% experienced at least one moderate or severe exacerbation in the 12-month baseline period, 9.5% visited the emergency department for COPD-related reasons; and 12.7% were hospitalized for COPD (median length of stay 7 [interquartile range: 6– 8] days). Patients initiating single-inhaled BGF triple therapy escalated from monotherapy (2.3%) or dual therapy (62.7%), switched from other triple therapies (31.3%), or were treatment-naïve (3.7%). Conclusion: Single-inhaler BGF triple therapy was initiated mostly as an escalation from dual maintenance therapy, with many switching from triple therapy, in patients with a high burden of disease, as demonstrated by their frequent exacerbation profile, advanced COPD severity (moderate to very severe obstruction) and the high frequency of several comorbidities, including cardiovascular diseases.


  • Open Access

    Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study

    by Michael Pollack, Eleni Rapsomaniki, Antonio Anzueto, Kirsty Rhodes, Nathaniel M. Hawkins, Claus F. Vogelmeier, Jonathan Marshall, Hana Müllerová


  • Late Breaking Abstract - Prompt initiation of budesonide/glycopyrronium/formoterol reduces exacerbations and cardiopulmonary events in patients with COPD (MITOS EROS+CP study)

    by Michael Pollack, Joseph Tkacz, Jill Schinkel, Barnabie Agatep, Edward Portillo, Hayley Germack, Michael Crooks, Charlie Strange, Jonathan Marshall, Hana Mullerova

    Rationale: Timely initiation of therapy reduces risks of acute COPD exacerbations (AECOPD). This study examined whether prompt initiation of single inhaler triple therapy (SITT) with budesonide/glycopyrronium/formoterol fumarate (BGF) following an AECOPD also lowers risk of future AECOPD and severe cardiopulmonary (CP) events. Methods: This retrospective study used US claims data from patients with COPD who were ≥40 years with no prior SITT and either: ≥1 severe or ≥2 moderate AECOPD, or ≥1 moderate AECOPD while on non-SITT treatment (earliest event = index date); all patients initiated BGF within 1-year following index. Outcomes were annualized rates per person/year of AECOPD and severe CP events. Severe CP events included mortality, severe AECOPD and hospitalizations for HF, AMI, and cardiac arrest. Descriptive results were presented and stratified by BGF initiation: prompt (≤30 days), delayed (31–180 days), and very delayed (181–365 days). Results: 17613 patients qualified: 2192 prompt, 7230 delayed, and 8191 very delayed. The rate per person/year (95% CI) of post-index AECOPD increased as the time to BGF initiation increased: prompt 1.35 (1.30–1.40); delayed 1.77 (1.74–1.79); and very delayed 1.98 (1.95–2.00). Total severe CP event rates were: prompt 0.34 (0.32–0.37); delayed 0.39 (0.38–0.40); and very delayed 0.38 (0.37–0.39). Conclusion: Promptly initiating BGF was associated with 24% and 32% fewer subsequent AECOPD and 12.3% and 9.3% fewer severe CP events compared with delayed and very delayed groups. Proactive disease management with BGF may be warranted to prevent future AECOPD and CP events among patients with COPD.

  • Open Access

    Patterns of Rescue and Maintenance Medication Claims Surrounding an Asthma Exacerbation in Patients Treated as Intermittent or Mild Persistent Asthma

    by Miguel J Lanz, Michael Pollack, Ileen Gilbert, Hitesh N Gandhi, Joseph P Tkacz, Njira L Lugogo

    Purpose: To examine patterns of short-acting ß2-agonist (SABA) and maintenance therapy claims surrounding the subset of severe asthma exacerbations associated with outpatient, urgent care, or emergency department visits or hospitalization (termed serious exacerbations) in patients treated as intermittent or mild persistent asthma. Methods: This was a retrospective study of 2010– 2017 administrative claims from MerativeTM MarketScan® US databases for patients ≥ 12 years filling a SABA prescription for asthma (index). Patients had ≥ 12 months continuous insurance eligibility pre- and post-index and ≥ 1 additional SABA and/or maintenance medication fill appropriate for mild persistent asthma post-index. Prescription fills were assessed over 30 days before and after a serious exacerbation event. Results: Of 323,443 patients (mean [standard deviation] age: 34.9 [18.2] years; 62.0% female) treated as intermittent or mild persistent asthma, 51,690 (16.0%) experienced ≥ 1 serious exacerbation post-index. During the 30 days pre-event, a greater proportion of patients filled a SABA versus maintenance therapy (24.6% vs 19.0%; odds ratio [OR]: 1.39, 95% confidence interval [CI]: 1.35– 1.43; p < 0.001); during the 30 days post-event, patients were more likely to fill maintenance medication versus SABA (88.6% vs 67.0%; OR [95% CI]: 3.88 [3.75– 4.01]; p < 0.001). The closer in time prior to the event, the greater the likelihood of filling a SABA versus maintenance prescription (OR [95% CI]; 1– 7 days pre-event: 1.42 [1.36– 1.48]; 8– 14 days pre-event: 1.34 [1.27– 1.41]; 15– 30 days pre-event: 1.18 [1.12– 1.24]; all p < 0.001). Over 4.5 times more patients filled a maintenance therapy within 7 days post-event (45,014) versus all 30 days pre-event (9835) (OR [95% CI]: 28.7 [27.7– 29.7]; p < 0.001). Conclusion: These patterns of SABA rescue and maintenance fills suggest that a “window of opportunity” may exist to interrupt a serious exacerbation occurrence for patients treated as intermittent or mild persistent asthma if symptoms and inflammation are addressed concomitantly.


  • Open Access

    Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study [Corrigendum]

    by Charlie Strange, Joseph Tkacz, Jill Schinkel, Benjamin Lewing, Barnabie Agatep, Sean Swisher, Sushma Patel, Devechio Edwards, Daniel R Touchette, Edward Portillo, et al.

    Corrigendum for the article Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study

  • Open Access

    Disease Burden and Health-Related Quality of Life (HRQoL) of Chronic Obstructive Pulmonary Disease (COPD) in the US – Evidence from the Medical Expenditure Panel Survey (MEPS) from 2016-2019

    by Melissa H Roberts, David M Mannino, Douglas W Mapel, Orsolya Lunacsek, Shahla Amin, Eileen Farrelly, Norbert Feigler, Michael F Pollack

    Purpose: Chronic obstructive pulmonary disease (COPD) is a progressive disease associated with reduced life expectancy, increased morbidity, mortality, and cost. This study characterized the US COPD burden, including socioeconomic and health-related quality of life (HRQoL) outcomes. Study Design and Methods: In this retrospective, cross-sectional study using nationally representative estimates from Medical Expenditures Survey (MEPS) data (2016– 2019), adults (≥ 18 years) living with and without COPD were identified. Adults living without COPD (control cohort) and with COPD were matched 5:1 on age, sex, geographic region, and entry year. Demographics, clinical characteristics, socioeconomic, and generic HRQoL measures were examined to include a race-stratified analysis of people living with COPD. Results: A total of 4,135 people living with COPD were identified; the matched dataset represented a weighted non-institutionalized population of 11.3 million with and 54.2 million people without COPD. Among people living with COPD, 66.3% had ≥ 1 COPD-related condition; 62.7% had ≥ 1 cardiovascular condition, compared to 33.5% and 50.5% without COPD. More people living with COPD were unemployed (56.2% vs 45.3%), unable to work due to illness/disability (30.1% vs 12.1%), had problems paying bills (16.1% vs 8.8%), reported poorer perceived health (fair/poor: 36.2% vs 14.4%), missed more working days due to illness/injury per year (median, 2.5 days vs 0.0 days), and had limitations in physical functioning (40.1% vs 19.4%) (all P< 0.0001). In race-stratified analyses for people living with COPD, people self-reporting as Black had higher prevalence of cardiovascular-risk conditions, poorer socioeconomic and HRQoL outcomes, and higher healthcare expenses than White or Other races. Conclusion: Adults living with COPD had higher clinical disease burden, lower socioeconomic status, and reduced HRQoL than those without, with greater disparities among Black people living with COPD compared to White and other races. Understanding the characteristics of patients helps address care disparities and access challenges.